F
Francisco Sanchez-Vega
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 115
Citations - 20975
Francisco Sanchez-Vega is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 36, co-authored 84 publications receiving 13474 citations. Previous affiliations of Francisco Sanchez-Vega include Washington University in St. Louis & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma
Jian Zhou,Jian Zhou,Francisco Sanchez-Vega,Raul Caso,Kay See Tan,Whitney S. Brandt,Gregory D. Jones,Shi Yan,Prasad S. Adusumilli,Matthew J. Bott,James Huang,James M. Isbell,Smita Sihag,Daniela Molena,Valerie W. Rusch,Walid K. Chatila,Natasha Rekhtman,Fan Yang,Marc Ladanyi,David B. Solit,Michael F. Berger,Nikolaus Schultz,David R. Jones +22 more
TL;DR: NPA and specific pathway alterations are associated with clinicopathologic features in patients with surgically resected lung adenocarcinoma and Cell cycle, Hippo, TGFβ, and p53 pathway alterationsAre associated with poor DFS, and NPA is an independent risk factor forpoor DFS in this cohort.
Journal ArticleDOI
Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma.
Chen Yang,Francisco Sanchez-Vega,Jason C. Chang,Walid K. Chatila,Alexander N. Shoushtari,Marc Ladanyi,William D. Travis,Klaus J. Busam,Natasha Rekhtman +8 more
TL;DR: In this paper, the authors investigated clinicopathologic and genomic features of lung-only melanomas with the goal to clarify their site of origin, and found that the clinical and pathologic features of solitary melanomas, especially those with large size and epithelioid morphology, closely mimicked primary lung carcinomas, highlighting a major potential for misdiagnosis.
Journal ArticleDOI
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Alexander N. Shoushtari,Alexander N. Shoushtari,Walid K. Chatila,Walid K. Chatila,Arshi Arora,Francisco Sanchez-Vega,Havish S. Kantheti,Jorge A. Rojas Zamalloa,Penina Krieger,Margaret K. Callahan,Margaret K. Callahan,Allison Betof Warner,Allison Betof Warner,Michael A. Postow,Michael A. Postow,Parisa Momtaz,Parisa Momtaz,Suresh G. Nair Md,Charlotte E. Ariyan,Christopher A. Barker,Mary S. Brady,Daniel G. Coit,Neal Rosen,Neal Rosen,Paul B. Chapman,Paul B. Chapman,Klaus J. Busam,David B. Solit,David B. Solit,Katherine S. Panageas,Jedd D. Wolchok,Jedd D. Wolchok,Nikolaus Schultz +32 more
TL;DR: In this paper, a Cox proportional hazards model was constructed for TTF using driver group and clinical variables, and nine driver groups varied by clinical presentation and mutational burden, with worse outcomes for NRAS Q61 and BRAF V600 versus NF1 or other alterations.
Journal ArticleDOI
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
Walid K. Chatila,Jin-Ki Kim,Henry Walch,Michael R. Marco,Chin-Tung Chen,Fan Wu,Dana Omer,Danny N. Khalil,Karuna Ganesh,Xuan Qu,Anisha Luthra,Seo Hyun Choi,Yu-jui Ho,Ritika Kundra,Katharine I Groves,Oliver S. Chow,Andrea Cercek,Martin R. Weiser,Maria Widmar,Iris H Wei,Emmanouil P. Pappou,Garrett M. Nash,Philip B. Paty,Qian Shi,Efsevia Vakiani,S. Duygu Selcuklu,Mark T.A. Donoghue,David B. Solit,Michael F. Berger,Jinru Shia,Raphael Pelossof,Paul B. Romesser,Rona Yaeger,J. R. Smith,Nikolaus Schultz,Francisco Sanchez-Vega,Julio Garcia-Aguilar +36 more
TL;DR: In this article , the authors analyzed genomic and transcriptomic profiles of 738 untreated rectal cancers and identified biomarkers of response that could inform patient selection for non-operative treatment strategies.
Journal ArticleDOI
Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene
Cristina Montero-Conde,Luis J Leandro-García,Xu Chen,Gisele Oler,Sergio Ruiz-Llorente,Mabel Ryder,Iñigo Landa,Francisco Sanchez-Vega,Konnor La,Ronald Ghossein,Dean F. Bajorin,Jeffrey A. Knauf,Jesse D. Riordan,Adam J. Dupuy,James A. Fagin +14 more
TL;DR: Sleeping Beauty (SB) transposon mutagenesis was used to identify events that cooperate with HrasG12V in thyroid tumor development and provided strong functional support for genetic disruptions in these pathways in RAS-induced thyroid tumor progression.